A Form 4 filed on September 8, 2026 with the SEC reports that Najat Khan, CEO and President of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), disposed of 22,408 shares of Class A Common Stock on September 8, 2026 under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Najat Khan, Director, CEO and President of Recursion Pharmaceuticals, Inc.
  • Shares sold: 22,408 shares of Class A Common Stock disposed of (transaction code S) on September 8, 2026.
  • Weighted average sale price: $3.5176 per share, with individual trades ranging from $3.485 to $3.58.
  • Shares retained: 2,072,890 shares of Class A Common Stock beneficially owned directly following the transaction.
  • Rule 10b5-1 plan: The sale was executed pursuant to a trading plan adopted by the reporting person on September 22, 2025.

Khan's Share Sale Details at Recursion Pharmaceuticals

According to the filing, Najat Khan, who serves as Director, CEO and President, disposed of 22,408 shares of Recursion Pharmaceuticals Class A Common Stock on September 8, 2026. The transaction carried code "S," indicating a sale. The filing discloses that the transaction was executed in multiple trades at prices ranging from $3.485 to $3.58, with the weighted average sale price reported as $3.5176 per share.

The filing notes that the transaction was made pursuant to a Rule 10b5-1 trading plan that Khan adopted on September 22, 2025. The filing further states that Khan "undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price." No derivative securities transactions were reported in Table II of the filing.

Following the reported transaction, the filing discloses that Khan directly beneficially owns 2,072,890 shares of Class A Common Stock. The Form 4 was signed by Kyle Nelson as attorney-in-fact on September 8, 2026.

What Was Disclosed

This Form 4 discloses the sale of 22,408 shares of Recursion Pharmaceuticals Class A Common Stock by CEO and President Najat Khan at a weighted average price of $3.5176, conducted under a Rule 10b5-1 plan established in September 2025, leaving Khan with 2,072,890 directly held shares.